Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2024.
Samit Hirawat, M.D., executive vice president, chief medical officer, Drug Development, will take part in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida, on Wednesday, March 13, 2024. He will answer questions about the company beginning at 10:00 a.m. ET.
Lynelle Hoch, president, Cell Therapy Organization, and Wendy Short Bartie, senior vice president, U.S. Hematology and Oncology, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami Beach, Florida, on Thursday, March 14, 2024. They will answer questions about the company beginning at 8:30 a.m. ET.
Investors and the general public are invited to listen to both sessions at their respective times by visiting http://investor.bms.com. An archived edition of each session will be available following its conclusion.
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER). The dermatology portfolio saw accelerated growth in revenue of 16%. The acquisition of TMB-001 to the treatment of congenital ichthyosis added a late-stage...
Hansa Biopharma AB (publ), ("Hansa" or the "Company") (STO: HNSA) today announced that the company's registered share capital and number of shares and votes have increased through the issue of 10,474,740 new ordinary shares on 12 April 2024, whereby...
Vicore Pharma Holding (STO:VICO) Stockholm, May 3 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim...
Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have...
The United States of America and ReNew Health Group LLC have settled a nursing home whistleblower claim involving allegations that the nursing home chain submitted false Medicare claims.
We need transparency and accountability in our nursing homes....
